Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC
A randomized Phase II trial from National Taiwan University Hospital reports early evidence that resecting the primary thoracic tumor following EGFR tyrosine kinase inhibitor (TKI) therapy may prolong disease control in patients ...
Sep 9, 2025
0
10









